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Summary Although medulloblastoma and neuroblastoma share many common biological, histological and
immunological features, the frequency of N-myc amplification differs markedly between the two tumours. In
this study, Southern blot analysis revealed that the N-myc gene was not amplified in any of the nine
medulloblastoma samples analysed. In contrast, over-expression of the gene was found in six of 11 samples as
determined by immunocytochemistry and/or Western blot analysis, using an antiserum raised against a
synthetic peptide representing a sequence unique to the N-myc gene product. The specificity of this reagent
was demonstrated by studies on a variety of cell lines expressing N-myc and/or c-myc oncoproteins. Of the 12
medulloblastoma samples collected over a two-year period and analysed in the course of this project, a trend
towards longer disease-free survival was noted in the patients having low levels of the N-myc protein in their
tumour.
Following the original report of N-myc amplification in
neuroblastoma, other neuroectoderm derived tumours have
been shown either to carry the amplification or to
overexpress the gene. Amplification has been noted in a case
of a paediatric astrocytoma (Garson et al., 1985) and
increased expression reported in both fetal brain (Grady et
al., 1987) and retinoblastoma (Lee et al., 1984). Certain non-
neuroectoderm derived tumours such as embryonal
rhabdomyosarcoma have also been shown to carry amplified
sequences of N-myc (Garson et al., 1986; Mitani et al.,
1986). In addition, specimens of Wilm's tumours and
teratomas have been shown to overexpress the N-myc gene
(Nisen et al., 1986; Jakobovits et al., 1985). These
observations, along with the finding that only some 38% of
stage III and IV tumours show N-myc amplification, have
reduced the diagnostic significance of this molecular
abnormality (Brodeur et al., 1988). However, information
regarding the N-myc status of neuroblastoma has been
shown to be of prognostic importance. Of particular
relevance is the observation that patients with Evans stage II
disease, that carry the amplification, have a poorer outcome
than those with a single copy of the N-myc gene per haploid
genome (Seeger et al., 1985). Further information concerning
the diagnostic and prognostic importance of N-myc would
become available if overexpression of the gene was also
investigated. Unfortunately, many tumour biopsies do not
lend themselves to this type of analysis due to the labile
nature of RNA.
Within the past two or three years, immunological
approaches to studying the c-myc and N-myc proteins have
become available. Ikegaki et al. (1986) used monoclonal
antibodies raised against a bacterially expressed lac z fusion
protein containing a portion of the N-myc sequence to detect
nuclear staining in the neuroblastoma cell line IMR5.
Similarly, Slamon et al. (1986) raised a rabbit antiserum
against a bovine growth hormone/N-myc fusion protein and
reported nuclear staining in cell lines and biopsy samples
from tumours known to amplify and overexpress the N-myc
gene. Using an alternative approach, Ramsay et al. (1986)
described an antiserum raised against a synthetic peptide
representative of a sequence present in the N-myc gene. This
reagent was reported to detect the N-myc protein in standard
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biochemical procedures, but not to bond to the nuclear
protein in immunocytochemical studies.
Medulloblastoma is a tumour of neuroectoderm origin,
with some biochemical and immunological features in
common with neuroblastoma (Rorke et al., 1986). Only
occasional, single case reports of N-myc expression in this
malignancy have been published previously (Nisen et al.,
1986). In addition, c-myc amplification has been observed in
the medulloblastoma-derived cell line D341 (Friedman et al.,
1988). In this paper we detail studies on N-myc amplification
and expression in 12 medulloblastoma biopsies. Controls
using cell lines expressing either the N-myc and/or c-myc
proteins have revealed approximately 50% of the samples
analysed overexpress the N-myc gene.
Materials and methods
Tissues and sections
Tissues taken at operation were immediately cut into 2-3 mm
blocks, placed into freezing vials and dropped into liquid
nitrogen. Cryostat sections (5-6,um) were placed on to
gelatine coated slides and stained with antisera to the N-myc
gene product as described below. In addition, Haematoxylin
and Eosin sections were prepared to ensure that tissues used
for Southern and Western blot analysis consisted of viable
tumour. Histological confirmation of the diagnosis was
provided by the Department of Neuropathology, Frenchay
Hospital, Bristol, United Kingdom.
Cell lines
The human neuroblastoma cell line was a gift from Dr P.
Rabbitts, Ludwig Institute, Cambridge, UK, and the
medulloblastoma cell line T671 was a gift from Dr Zeltser,
UCLA, Los Angeles, USA. These lines, along with the
colorectal carcinoma line, COLO 320.DM, were grown at
37°C in a 6% CO2 adherent cultures using RPMI 1640
supplemented with 10% fetal calf serum 100IUml-1 of
penicillin and 100pgml-1 of streptomycin.
The T-cell leukaemic line GH1 and the promyelocytic
leukaemic line HL60 were grown as suspension cultures in
the medium described above. All cell lines were harvested in
exponential growth phase for studies in N-myc and c-myc
expression. The Kelly (YK) cell lines carries 100-fold
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amplification of the N-myc gene and overexpresses N-myc
RNA (Shwab et al., 1983). The HL 60 and COLO 320.DM
cells over-express the c-myc gene product (Boultwood et al.,
1988; Erisman et al., 1988). The T-cell line GHl does not
express either c-myc or N-myc as determined by Northern
blot analysis (unpublished observation).
Southern blot analysis
DNA was prepared from tissues and cell lines using standard
techniques (Mantiatis et al., 1982). This was digested with
EcoRI and fragments separated by agarose gel
electrophoresis. DNA was transferred to gene screen solid
support and this was incubated with the N-myc probe pNb-I
labelled with 32P by the oligo-labelling technique of Feinberg
& Vogelstein (1983). After washing the blots at high
stringency, autoradiographs were exposed for 48h on
preflashed Kodak XAR-5 film with an intensifier screen. The
N-myc gene copy number was estimated relative to placental
DNA single copy intensity and molecular weights were
calculated from lambda Hind III restriction fragment
standards.
Antiserum to the N-myc protein
Antisera were raised to: (1) a synthetic peptide representing
an amino acid sequence unique to the N-myc gene product
(reference: OA-11-803); (2) a synthetic peptide representing
an amino acid sequence largely conversed in the N-myc, c-
myc and L-myc oncoproteins (reference: OA-11-801).
The sequences are identified and their relative positions in
exons 2 and 3 from c-myc, N-myc and L-myc are given in
Figure 1. OA-11-803 was affinity purified against the N-myc
peptide.
Immunocytochemical staining
Cryostat sections (6pm) or cytospin preparations on gelatine
coated slides were fixed for 5min in 3.7% formaldehyde/
phosphate buffered saline (PBS). Slides were treated with
2.5% Triton X-100 in PBS for 10min and non-specific
protein binding blocked by incubation with 10% normal
rabbit serum (NRS) in PBS for 10min. Incubation with
either affinity purified sheep anti N-myc (1:100 dilution of
OA-11-803 in PBS/i % NRS) or the pan-myc antiserum OA-
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Figure 1 Sequence of the peptides used to generate the N-myc
specific and pan-myc hetero-antisera. The N-myc, c-myc and L-
myc genes consist of three exons. Part of exon 2 and 3 are
transcribed and translated to form the relevant myc protein. The
sequence used to generate the pan-myc reagent was taken from a
coding region in exon 2. The homology between the N-myc, c-
myc and L-myc sequences is illustrated. The sequence used to
generate the N-myc specific reagent was taken from a coding
region in exon 3. The comparative c-myc, N-myc and L-myc
sequences are illustrated, indicating the restricted nature of the
N-myc sequence. c-myc sequence (Watt et al., 1983); N-myc
sequence (Stanton et al., 1986); L-myc sequence (Ibson et al.,
1987).
11-801 (1:100 dilution of OA-11-801 in PBS/1% NRS) was
performed overnight at 40C.
Following three washes in PBS, the slides were incubated
at room temperature for 1 h with biotin conjugated rabbit
anti-sheep Ig (Vector BA 6000) diluted to 1:300 in PBS
containing 1% NRS, 1% normal mouse serum and 1%
normal human serum. The slides were washed a further three
times in PBS and incubated for 30min with avidin/biotin/
peroxidase complex (Dako ABC reagent K355). After
washing three times, the chromogen/substrate solution
(0.5mgml-1 diaminobenzidine in PBS with 0.02% H202)
was applied for 5-10min. The reaction was terminated by
washing in PBS and slides mounted in Dako 'Glycergel'.
Antiserum preincubated with a 100-fold molar excess of the
immunising peptide was used as a negative control in all
experiments.
Western blot analysis
Tissues and cell lines in exponential growth phase were
homogenised on ice in extraction buffer containing 10%
glycerol, 0.1M Tris-HCl pH 6.8, 1mM EDTA, 2% SDS fi-
mercaptoethanol, 1mM phenylmethylsulphonylfluoride and
20pgml-1 Leupeptin. The lysates were boiled for 3min and
subsequently centrifuged for 15min at 10,000g. Supernatants
were stored at -70°C for up to three weeks. The protein
content of the supernatants was estimated by the method of
Bradford (1976). Aliquots (50pg) were loaded on to each
lane of an 8% polyacrylamide gel (13cmx8cmxl.5mm)
and electrophoresis carried out in the presence of SDS
(Laemmli, 1970) at 20V for 16h. The gel was electroblotted
on to 0.1 pm pore size nitrocellulose at I00V for 5h at 15°C.
Efficiency of transfer was assessed by Coomassie staining of
the gel after blotting and by staining one lane of the
nitrocellulose filter for total protein, by the Indian ink
method of Hancock et al. (1983).
Non-specific protein binding sites on the filter were
blocked by incubation overnight in PBS/0.05% Tween 20
(Batteiger et al., 1982). Incubation with OA-11-803 (sheep
antibody to N-myc) or OA-11-801 (sheep antibody to pan-
myc) antisera diluted 1:200 in PBS/10% normal rabbit
serum (or peptide absorbed control) was performed for
90min at room temperature, followed by three washes, 5min
each, in PBS. The filter was subsequently incubated with
either biotinylated or alkaline phosphatase conjugated rabbit
anti-sheep Ig, diluted 1:2000 in PBS 10%/NRS for 1 h at
RT. When the biotinylated second layer was used, this was
followed by a 30min incubation with Streptavidin
conjugated alkaline phosphatase diluted 1:1000 (BRL, Blue
Gene Reagent). Colour development was performed in the
dark by incubating the strips for 5-30min in substrate
solution. The chromogenic substrate was made up by adding
4.4p1 Nitroblue tetrazolium (NBT) (at 75mgml-1 in 70%
dimethylformamide and 3.3pl 5-bromo-4-chloro-3-indolyl
phosphate (BCIP) (at 50mgml-1 in dimethylformamide) to
1 ml of 0.1 M Tris HCI buffer pH 9.5 containing 0.1 MNaCl
and 50mMMgC12.
Results
A total of 12 medulloblastoma cases were examined. Due to
the limited amount of fresh tissue available, it was not
possible to perform all investigations in each case.
Southern blot analysis
Following DNA extraction from medulloblastoma tissue and
EcoRI digestion, faint 2kb bands were identified as
hybridising to the N-myc probe in all samples analysed
(n=9). Figure 2 illustrates six samples (lanes 2-7). These
were estimated to be of single copy intensity per haploid
genome, as a comparable signal was obtained from human
placental DNA (Figure 2, lane 1). As a positive control, an
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Figure 2 Southern blots showing a single copy N-myc gene in
medulloblastoma tissue. Lane 1, contains 10pg of placental
DNA and shows a 2kb band hybridised to the N-myc probe
NBI, single copy intensity. Lanes 2-7, each lane contains 10pg
of DNA from different medulloblastomas. A 2Kb band of single
copy intensity hybridised to the N-myc probe NB1 is identified in
each lane. Lane 8, contains 10pg of DNA from a stage IV
neuroblastoma showing an approximate 50-fold amplification of
the N-myc gene.
intense 2kb signal was obtained from DNA isolated from a
stage IV neuroblastoma carrying a 50-fold amplification of
the N-myc gene. Similar experiments using the c-myc probe
pUCLYXh16 also revealed no amplification of the c-myc
gene. EcoRl digests of DNA probed with pUCLYXhl6
revealed two bands of 10 and 6kb of comparable intensity
to the signal obtained from human placental DNA (data not
presented).
To control for loading errors on the gels, blots were
washed and re-proved with the DNA probe L2.30. This
binds to a 2.2kb EcoRl fragment present as a single copy
per haploid genome. Bands of equal intensity were obtained
in all tracks analysed.
N-myc gene expression
The relative level of the N-myc protein was determined by a
combination of immunocytochemical and biochemical
techniques. Immunocytochemistry, using the affinity purified
anti N-myc specific antiserum (OA-11-803), revealed dense
nuclear staining of the Kelly neuroblastoma cell line known
to carry a 100-fold amplification and to overexpress the N-
myc gene. Within this population, there was considerable
heterogenity in the staining observed from cell to cell. The
N-myc gene product was selectively localised to the nucleus,
as neither the cytoplasm or nucleoli appeared to bind the
reagent (Figure 3a). In contrast, no staining of the Kelly cell
line was observed when the antiserum was premixed with a
100-fold molar excess of the immunising peptide (Figure 3b).
The promyelocytic leukaemia cell line HL60 and the
colorectal carcinoma cell line COLO 320 DM did not bind
OA-11-803, illustrating that the antiserum does not cross
react with the c-myc protein (Figure 3c). In addition, no
binding was observed using the GHI cell line that does not
constitutively express either c-myc or N-myc (Figure 3d).
Analysis of medulloblastoma tissue sections revealed
nuclear staining in 6/10 samples screened (Figure 4). Four
samples gave background staining similar to that seen on
Figure 3 Anti N-myc antiserum OA-11-803 binding to cells
expressing the N-myc protein. (a) The human neuroblastoma cell
line Kelly containing multiple copies of the N-myc gene and
elevated levels of N-myc mRNA. Binding of OA-11-803 is
restricted to the nucleus. (b) As (a) but using OA-11-803
preincubated with a 100-fold molar excess of the synthetic
peptide used as an immunogen. (c) Binding of OA-11-803 to the
human leukaemic T-cell GH1. (d) Binding of OA-11-803 to the
promyelocytic cell line HL60. Similar data were obtained for the
cell line COLO 320.DM.
tissues such as lymphoma (n=3) and tonsil (n=4) which is
known not to express the N-myc gene. Binding of the
antiserum in the six positive samples could be blocked by
preincubation of the antiserum with an excess of synthetic
peptide.
No staining of a bank of formalin-fixed and paraffin-
embedded medulloblastoma tissue was observed using either
the pan-myc or N-myc specific antisera, indicating that the
N-myc protein is either denatured or degraded during
fixation.
Western blot analysis of the N-myc protein
To confirm that antiserum OA-11-803 actually recognises the
N-myc gene product, medulloblastoma biopsies were
homogenised and subjected to Western blot analysis. Figure
5 illustrates a typical result along with controls undertaken
to ensure specificity of binding. A 63-66 kD doublet was
observed binding to the N-myc specific antiserum OA-l1-
803. This is the normal positions of the N-myc protein(s) as
determined by polyacrylamide gel electrophoresis. In
addition, a 58kD band was observed (Figure 5, lane A),
which is considered to be a putative breakdown product of
the N-myc gene. The intensity of this band varied from
sample to sample. All other bands observed on the gels were
due to non-specific binding of the antiserum, as they could
not be removed following pre-incubation of OA-11-803 with
Figure 4 Anti N-myc antiserum OA-11-803 binding to frozen
sections ofmedulloblastoma. (a) Medulloblastoma tissue showing
nuclear staining with antiserum OA-11-803. (b) As (a) but using
OA-11-803 pre-incubated with a 100-fold molar excess of the
synthetic peptide used as an immunogen. (c) Binding of OA-l1-
803 to lymphoma tissue.892 J.A. GARSON et al.
a 100-fold molar excess of the immunising peptide (Figure 5,
lane B). Only the 63-66kD proteins could be identified when
antibody binding was visualised using an alkaline
phosphatase rabbit anti-sheep Ig conjugate. However, the
signal obtained under these circumstances was weak and,
therefore, an additional amplification step was used to
enhance photographic recording.
The 63-66kD bands were only observed in
medulloblastoma cell extracts shown to contain the N-myc
protein by immunocytochemical analysis. In addition, no 63-
66kD doublet was apparent in extracts of the GH1 T-cell
line, not expressing either c- or N-myc (Figure 5, lane C). As
a positive control for these studies, extracts of the
neuroblastoma cell line Kelly were also analysed by Western
blot. OA-11-803 specifically bound to the 63-66 kD N-myc
doublet and also showed weak reactivity to the 58kD
protein (Figure 5, track D). Binding to these proteins was
again abolished by prior incubation of the antiserum with an
excess of synthetic peptide (Figure 5, lanes D and E).
Indirect evidence that the protein being detected in the
medulloblastoma tissues was N-myc is provided by analysing
cell extracts from cell lines (COLO 320.DM and HL60)
constitutively expressing the c-myc protein. No bnding was
observed with OA-11-803, although the pan-myc antibody
OA-11-801 did bind to the 63-66kDa c-myc doublet (Figure
6).
Clinical correlates
Two of the patients in this study died from causes not
directly related to their tumour and a third was lost to
follow-up. Of the remaining nine cases, five had tumours in
which the N-myc gene product was identified and four had
tumours with no evidence of gene expression. These two
groups were well matched for age, site of tumour and degree
of tumour resection and yet all patients with no detectable
N-myc gene expression remain alive and well 8-54 months
from the completion of treatment (Table I). In contrast, 3/5
patients with demonstrable constitutive N-myc protein levels
have died 7-54 months from initial therapy. The other two
remain disease-free 36 and 55 months from the end of
treatment. While the patient group is too small to be certain
of the significance of these observations, there is a trend
towards better survival in the group of patients in which the
N-myc gene product was absent.
Discussion
Medulloblastomas and neuroblastomas share many common
biological, histological and immunological features (Rorke et
al., 1986). Both tumour types may exhibit karyotypic
abnormalities known as double minute chromosomes (Cox et
al., 1965). In neuroblastomas, these, along with
homogenously staining regions (HSR), have been shown to
be the sites of amplification of the N-myc oncogene.
Although we have not undertaken cytogenetic studies on the
medulloblastomas, reported here by Southern blot analysis,
they do not contain either amplified N-myc or c-myc genes.
In addition, in our hands the human medulloblastoma cell
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Figure 5 Western blot analysis of the N-myc protein in
medulloblastoma tissue using an anti-N-myc antiserum
(OA:11:803). Lane A, illustration of medulloblastoma extract
binding antiserum OA-11-803. Lane B, as lane A, but using
antiserum OA-11-803 pre-incubated with a 100 fold molar excess
of the synthetic peptide used as an immunogen. Lane C, extract
from the human neuroblastoma cell line Kelly incubated with
OA-11-801 containing a 100-fold molar excess of the synthetic
peptide used as an immunogen. Lane D, as lane C but using
antiserum OA-11-803. Lane E, extract from the T-leukaemic cell
line GH1 showing no 63-66kD band binding to the antiserum
OA-1 1-803.
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Figure 6 Western blot analysis of the c-myc protein in the
promyelocytic cell line HL60. Lane A, extract of the HL60 cell
line incubated with the pan-myc reagent OA-11-801. Lane B,
extract of the HL60 cell line incubated with the N-myc specific
reagent OA-11-803. Identical results to those illustrated were
obtained analysing extracts of COLO 320.DM.
Table I Summary of survival data and N-myc protein levels in
patients with medulloblastoma
Relapse-free N-myc N-myc
Age survival Current copy protein
Patient (months) (months) status number detected
1 10 41 Alive 1 -
2 30 8 Alive n.t. -
3 72 54 Alive 1 -
4 86 29 Alive 1 -
5 45 23 Dead 1 +
6 57 54 Dead 1 +
7 58 7 Dead 1 +
8 41 55 Alive n.t. +
9 102 36 Alive 1 +
10 60 0.5 Deada 1 n.t.
11 228 1 Deadb 1
12 n.a. n.a. n.a. n.t. +
Patients 10, 11 and 12 were excluded from the summary ofclinical
data; n.a., data not available; n.t., not tested due to insufficient
biopsy material.
aDied of post-operative cardiac arrest; bDied of bacterial
meningitis.N-myc GENE EXPRESSION 893
line TE671 does not carry amplified c-myc or N-myc genes
as determined by Southern blot analysis (data not
presented). This is in contrast to the finding of Friedman et
al. (1988) who demonstrated c-myc amplification in another
human medulloblastoma cell line D341.
In spite of the lack of N-myc amplification in the
medulloblastoma tissues studied, 50% of samples appeared
to be expressing the N-myc gene by immunohistological and
Western blot studies using the anti N-myc specific anti-serum
OA-11-803. Control studies on lines known to express either
c-myc or N-myc clearly demonstrated the specificity of this
reagent, as it does not bind to either c-myc in HL60 or
COLO 320.DM cell lines. Although these lines have been
shown to express c-myc, this was confirmed through the use
of the anti-pan-myc reagent OA-11-801. Medulloblastoma,
therefore, appears biologically different to neuroblastoma,
where N-myc overexpression has been linked with
amplification of the gene.
The immunohistological studies presented here were
confirmed by Western blot analysis. Only those tumours
expressing N-myc by immunohistological criteria were found
to contain the 63-66kD doublet characterised as the N-myc
protein(s). This biochemical data agrees with the findings of
other groups using both immunoblotting and
immunoprecipitation techniques, but is anomalous in that
the size of the N-myc protein predicted from its nucleic acid
sequence is only 49kD. The protein is known to be
phosphorylated but this modification is insufficient to
explain the discrepancy.
In addition to the 63-66kD doublet, we frequently
observed faint bands thought to represent N-myc
degradation products. These bands varied in intensity from
sample to sample. In view of the short half life of the N-myc
protein (t112 approx. 30min, Ramsay et al., 1986) it is
essential that tissues are frozen immediately in order to
avoid false negative results from either Western blot or
immunocytochemical studies. This makes accurate
quantification of N-myc protein levels extremely difficult.
The failure to detect the N-myc protein in conventional
formalin-fixed, paraffin-embedded sections may be due to
either denaturation or proteolysis, resulting from the
relatively slow diffusion of fixative into tissue and/or the use
of high melting point waxes. Initially, we had hoped that an
immunological approach to identify the N-myc gene product
would prove more reliable than studies of mRNA, but in
this instance both protein and mRNA are highly labile.
Seeger et al. (1985) have shown that N-myc amplification
in neuroblastoma is correlated with relapse-free survival. The
cause of this relationship remains speculative. This could be
due to either the generation of cytogenetic abnormalities
within the malignant cells (HSRs and DMs) or simply due to
the overexpression of the N-myc gene. Although the number
of cases presented here is small, a trend indicating that N-
myc expression is associated with a poorer prognosis is
evident. If substantiated, this would support the contention
that N-myc expression is the causal agent for the bad
prognosis seen in this group of patients (and by inference,
neuroblastoma patients) as none of the cases examined here
had amplified N-myc genes. If the association between N-
myc expression and poor prognosis is supported by future
studies, then N-myc expression might, like certain other
histopathologic and clinical variables (Gilles et al., 1986),
become an important guide to both prognosis and therapy.
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